Tata India Pharma & Healthcare Fund Regular-Growth
The fund is rated 1 star. The investment selection within each asset type and balance between returns and downside risk provided some support. The investment selection within each industry was the main limitation and did not provide enough support for a higher rating. A higher annual fee of 2.37% was a minor drawback.
This fund has a ok track record with Asset Selection/Timing, a bad track record with Stock Selection/Timing. It is important to note, however, that this fund has a 1565.28 AUM and a 2.37 expense ratio. Considering all these factors, we have rated this fund as 1.0 star.
અમારો સ્કોર લાંબા ગાળાની કામગીરી, જોખમ અને સાતત્યને વજન આપે છે — ફક્ત ભૂતકાળના વળતરને નહીં.
રિટર્ન
8 Oct 2026 મુજબ
જોખમ ગુણોત્તર
30 Sep 2026 મુજબ
પોર્ટફોલિયો
31 Aug 2026 મુજબ
માર્કેટ-કેપ વિભાજન
સેક્ટર ફાળવણી
હોલ્ડિંગ્સ (42)
| હોલ્ડિંગ | ફંડનો % | મૂલ્ય | શેર |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 8.43% | ₹132.02 Cr | 6,65,178 |
| Healthcare Global Enterprises Ltd. | 6.30% | ₹98.56 Cr | 13,44,012 |
| Divi's Laboratories Ltd. | 5.65% | ₹88.49 Cr | 93,472 |
| Abbott India Ltd. | 5.44% | ₹85.11 Cr | 32,924 |
| Rainbow Children's Medicare Ltd. | 4.47% | ₹70.04 Cr | 4,95,081 |
| Apollo Hospitals Enterprise Ltd. | 4.32% | ₹67.64 Cr | 76,013 |
| Cipla Ltd. | 4.27% | ₹66.78 Cr | 4,73,861 |
| Dr. Reddy's Laboratories Ltd. | 4.21% | ₹65.84 Cr | 5,70,312 |
| Max Healthcare Institute Ltd. | 3.80% | ₹59.55 Cr | 5,71,483 |
| Fortis Healthcare Ltd. | 3.30% | ₹51.63 Cr | 5,69,351 |
ફંડ વિગતો
Long Term Capital Appreciation. Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India.
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Exit load of 0.25% if redeemed within 30 days.